Coluracetam
From Wikipedia, the free encyclopedia
 |
|
|
Coluracetam
|
|
| Systematic (IUPAC) name | |
| N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxopyrrolidin-1-yl)acetamide | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C19H23N3O3 |
| Mol. mass | 341.404 g/mol |
| SMILES | search in , |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Unscheduled (US) |
| Routes | Oral |
Coluracetam is a nootropic drug of the racetam family. It may also have potential use in prevention and treatment of ischemic retinopathy and retinal and optic nerve injury.
[edit] See also
[edit] References
- Bessho T, Takashina K, Tabata R, Ohshima C, Chaki H, Yamabe H, Egawa M, Tobe A, Saito K: Effect of the novel high affinity choline uptake enhancer 2-(2-oxopyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetoamide on deficits of water maze learning in rats. Arzneimittelforschung 1996, 46(4), 369-73 PMID 8740080.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
